Employees: 1,256
Size Boji Medical Technology (300404.SZ) is a China Health Care company (Biotechnology) with a market value of $561M, the 3418th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.97 on 18 Nov 2026.
Performance Over six months the shares fell 6.5%, against -19.4% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 19 in its peer set.
Growth Revenue grew 31.9% over the last twelve months (peer median +5.7%); the operating margin is 3.7% (peer median -49.9%).
Valuation It trades at 69.3× forward earnings against a peer median of 21.9× (2nd most expensive of 7).
Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.6 points below its cost of capital (8.0% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.02B | CN¥865M | CN¥739M | CN¥554M | CN¥422M |
| Revenue growth | — | +17% | +33% | +31% | — |
| Gross profit | CN¥257M | CN¥212M | CN¥204M | CN¥166M | CN¥145M |
| EBITDA | n/a | CN¥52.3M | CN¥38.5M | CN¥25.0M | CN¥29.9M |
| Net income | CN¥57.9M | CN¥30.5M | CN¥28.8M | CN¥24.3M | CN¥27.7M |
| Free cash flow | CN¥55.1M | CN¥70.5M | CN¥448,420 | -CN¥23.6M | -CN¥86.2M |
| Capital expenditure | CN¥21.2M | CN¥18.7M | CN¥29.4M | CN¥62.2M | CN¥118M |
| Total debt | CN¥43.2M | CN¥46.4M | CN¥49.9M | CN¥116M | CN¥80.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300404.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.5% | -12.2% | 7th lowest of 21 |
| 6-month return | -6.5% | -19.4% | 6th highest of 19 |
| Distance from 52-week high | -44.6% | -49.8% | 9th highest of 21 |
| Revenue growth (TTM) | +31.9% | +5.7% | 5th highest of 17 |
| Operating margin | 3.7% | -49.9% | 6th highest of 17 |
| Forward P/E | 69.3× | 21.9× | 2nd most expensive of 7 |
| Growth the price implies (Req g, 7 yrs) | 31.9% | 21.9% | 2nd most demanding of 5 |
| Growth delivered (Del g) | +27.2% | +11.2% | 2nd highest of 5 |
| Hurdle (Req g minus delivered) | +4.7 pp | -4.4 pp | 2nd most demanding of 5 |
| ROIC minus cost of capital | -2.6 pp | -3.2 pp | 6th highest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Boji Medical Technology 300404.SZ | China | $561M | -6% | +32% | 4% | 69.3× | 31.9% | +27.2% |
| Sana Biotechnology SANA | United States | $554M | -41% | n/a | n/a | n/a | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $553M | -22% | +2% | 17% | 11.7× | n/a | n/a |
| Genfit GNFT.PA | France | $571M | +22% | +28% | -130% | 431.5× | 39.8% | +143.5% |
| Ascletis Pharma 1672.HK | Hong Kong | $571M | -72% | -59% | -71,976% | n/a | n/a | n/a |
| Wave Life Sciences WVE | United States | $546M | -55% | -35% | -321% | n/a | n/a | n/a |
| Climb Bio CLYM | United States | $546M | -12% | n/a | n/a | n/a | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $578M | +23% | +79,952% | -226% | n/a | n/a | n/a |
| Frontage 1521.HK | Hong Kong | $542M | +113% | +10% | 8% | 24.6× | 14.3% | +15.4% |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | n/a | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 22.3× | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | n/a | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $518M | -20% | -1% | -13% | n/a | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $510M | n/a | n/a | n/a | n/a | n/a | n/a |
| Valneva VLA.PA | France | $508M | -6% | -27% | -87% | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | n/a | -8.9% | -1.3% |
| Beijing Scitop Bio-Tech 300858.SZ | China | $501M | -28% | +4% | 8% | 21.5× | n/a | n/a |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 19.2× | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $494M | -19% | -17% | 0% | n/a | 29.4% | +7.0% |